Clinical trial

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

NCT04210037

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-08-20

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2020-08-20Date precision: day

Registry last updated2022-07-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancerunresolved

Interventions

APG-1252DRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Ascentage Pharma Group Inc.lead sponsor

Mapped research locations

BostonMassachusetts, United States1 ChicagoIllinois, United States1 AtlantaGeorgia, United States1 Ann ArborMichigan, United States1 FairfaxVirginia, United States1 PlantationFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04210037 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.